Ryan Flinn

Type: Person

Name: Ryan Flinn

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Dendreon Falls as Sales of Provenge Prostate Drug Miss Estimates

Dendreon Corp. (DNDN)Dendreon dropped (DNDN)First-quarter revenue fell 18 percent to $67.6 million, the Seattle-based company said in a statement today. Analysts expected sales of $79.7 million, the average of 19 estimates in a Bloomberg survey. Provenge, ... [Published BusinessWeek - May 09 2013]

Entities: Dendreon Corp, Prostate, Drugs, Ryan Flinn

First reported May 03 2013 - Updated May 04 2013 - 1 reports

Gilead Sciences Inc

Gilead Rises to Highest Price on Possible Hepatitis C Drug Sales

Gilead Sciences Inc. (GILD)Gilead gained 5.9 percent to $55.23 at 12:52 p.m. New York time, after earlier increasing to $56.35, its highest intraday value since the stock first started trading in 1992. The shares of the Foster City, California-based company ... [Published BusinessWeek - May 03 2013]

Entities: Gilead Sciences Inc, Hepatitis C, Drugs, Bret Holley, Ryan Flinn

First reported Apr 27 2013 - Updated Apr 28 2013 - 1 reports

Actavis

Valeant Said to Be in Merger Talks With Rival Actavis

(Adds ’said to’ in the headline and nature of talks in the fourth paragraph.)April 26 (Bloomberg) -- Valeant Pharmaceuticals International Inc. and Actavis Inc., two makers of generic drugs, have been in talks about a merger, people familiar with the ... [Published Washington Post - Apr 27 2013]

Entities: Actavis, Valeant Pharmaceuticals International, Cephalon Inc, Skincare, Ryan Flinn

First reported Mar 19 2013 - Updated Mar 19 2013 - 1 reports

Affymax Inc

Affymax Falls After Firing 75% of Workers - Bloomberg

Affymax Falls After Firing 75% of Workers Bloomberg “With limited funds and resources, the company may not be able to complete the investigation or ever identify the causes of the safety concerns,” Affymax said in the filing. To contact the reporter ... [Published Bloomberg via Google News - Mar 19 2013]

Entities: Affymax Inc, Workers, Ryan Flinn

First reported Feb 05 2013 - Updated Feb 05 2013 - 1 reports

Fidelity Said to Push Endo Health for Sale: Bloomberg

Fund manager Fidelity Investments is flexing some muscle, according to Bloomberg News: The company is reportedly pressing drugmaker Endo Health Solutions (ENDP) to consider selling itself after weak forecasts. Sasha Damouni, Ryan Flinn and Jeffrey McCracken ... [Published BARRONS.com Focus on Funds - Feb 05 2013]

Entities: Push, Ryan Flinn, Endo Health Solutions Inc

More Content

sort by: Date \| Relevance
Teva Jump on Actavis Widens Tel Aviv Discount: ... [Published La Repubblica - May 16 2013]
Dendreon Falls as Sales of Provenge Prostate Dr... [Published BusinessWeek - May 09 2013]
Gilead Rises to Highest Price on Possible Hepat... [Published BusinessWeek - May 03 2013]
Valeant Said to Be in Merger Talks With Rival A... [Published Washington Post - Apr 27 2013]
Affymax Falls After Firing 75% of Workers - Blo... [Published Bloomberg via Google News - Mar 19 2013]
Fidelity Said to Push Endo Health for Sale: Blo... [Published BARRONS.com Focus on Funds - Feb 05 2013]